Direct or early Discharge of Acute Bacterial Skin and Skin Structure Infection patients from the Emergency Department/Unit: place in therapy of dalbavancin

References

• Durante-Mangoni E, Gambardella M, Iula VD, et al. Current trends in the real-life use of dalbavancin: report of a study panel. Int J Antimicrob Agents. 2020 Oct;56(4):106107. Epub 2020 Jul 25. PMID: 32721599. DOI:10.1016/j.ijantimicag.2020.106107.
   PubMed Web of Science ®Google Scholar
• Weng QY, Raff AB, Cohen JM, et al. Costs and consequences associated with misdiagnosed lower extremity cellulitis. JAMA Dermatol. 2017;153(2):141–146. DOI:10.1001/jamadermatol.2016.3816.
   PubMed Web of Science ®Google Scholar
• Jensen IS, Wu E, Fan W, et al. Use of oritavancin in moderate-to-severe absssi patients requiring iv antibiotics: a u.s. payer budget impact analysis. J Manag Care Spec Pharm. 2016 Jun;22(6):752–764. PMID: 27231802. DOI:10.18553/jmcp.2016.22.6.752.
   PubMedGoogle Scholar
• Durante-Mangoni E, Riccardi A, Guarino M, et al. Emergency department care of ABSSSI with dalbavancin infusion, direct discharge, and outpatient telemedicine follow up: a study protocol. J Chemother. 2022 Oct;20:1–7. Epub ahead of print. PMID: 36264157. DOI:10.1080/1120009X.2022.2134616.
   Google Scholar
• Bosso JA, Casapao AM, Edwards J, et al. Clinical pathway for moderate to severe acute bacterial skin and skin structure infections from a US perspective: a roundtable discussion. Hosp Pract (1995). 2016 Oct;44(4):183–189. Epub 2016 Sep 12. PMID: 27598313. DOI:10.1080/21548331.2016.1230466.
   PubMedGoogle Scholar
• Bouza E, Valerio M, Soriano A, et al. DALBUSE Study Group (Dalbavancina: Estudio de su uso clinico en España), Dalbavancin in the treatment of different gram-positive infections: a real-life experience. Int J Antimicrob Agents. 2018 Apr;51(4):571–577. Epub 2017 Nov 24. PMID: 29180276. DOI:10.1016/j.ijantimicag.2017.11.008.
   PubMed Web of Science ®Google Scholar
• Bai F, Aldieri C, Cattelan A, et al. Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study). Expert Rev Anti Infect Ther. 2020 Dec;18(12):1271–1279. Epub 2020 Aug 14. PMID: 32797758. DOI:10.1080/14787210.2020.1798227.
   PubMed Web of Science ®Google Scholar
• Soriano A, Rossolini GM, Pea F. The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs). Expert Rev Anti Infect Ther. 2020 May;18(5):415–422. Epub 2020 Mar 29. PMID: 32223465. DOI:10.1080/14787210.2020.1746643.
   PubMed Web of Science ®Google Scholar
• Moet GJ, Jones RN, Biedenbach DJ, et al. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY antimicrobial surveillance program (1998–2004). Diagn Microbiol Infect Dis. 2007;57(1):7–13. DOI:10.1016/j.diagmicrobio.2006.05.009.
   PubMed Web of Science ®Google Scholar
• Morrissey I, Leakey A, Northwood JB. In vitro activity of ceftaroline and comparator antimicrobials against European and Middle East isolates from complicated skin and skin-structure infections collected in 2008–2009. Int J Antimicrob Agents. 2012;40(3):227–234.
   PubMed Web of Science ®Google Scholar
• Esposito S, De Simone G, Pan A, et al. Italian society of infectious and tropical diseases. epidemiology and microbiology of skin and soft tissue infections: preliminary results of a national registry. J Chemother. 2019 Feb;31(1):9–14. Epub 2018 Dec 3. PMID: 30508410. DOI:10.1080/1120009X.2018.1536320.
   PubMed Web of Science ®Google Scholar
• Lakhundia S, Zhang K. Methicillin-resistant staphylococcus aureus: molecular characterization, evolution, and epidemiology. Clin Microbiol Rev. 2018 Oct;31(4). e00020–18. DOI:10.1128/CMR.00020-18
   PubMed Web of Science ®Google Scholar
• Kock R, Friedrich A. On behalf of the original author Group C. Systematic literature analysis and review of targeted preventive measures to limit healthcare-associated infections by meticillin-resistant Staphylococcus aureus. Euro Surveill. 2014 Jul 24;19(29):20860. DOI: 10.2807/1560-7917.ES2014.19.37.20902.
   PubMedGoogle Scholar
• Talan DA, Salhi BA, Moran GJ, et al. Factors associated with decision to hospitalize emergency department patients with skin and soft tissue infection. West J Emerg Med. 2015;16(1):89–97. DOI:10.5811/westjem.2014.11.24133.
   PubMed Web of Science ®Google Scholar
• Poliseno M, Bavaro DF, Brindicci G, et al. Dalbavancin efficacy and impact on hospital length-of-stay and treatment costs in different gram-positive bacterial infections. Clin Drug Investig. 2021 May;41(5):437–448.
   PubMed Web of Science ®Google Scholar
• Aubert CE, Rodondi N, Terman SW, et al. HOSPITAL score and LACE index to predict mortality in multimorbid older patients. Drugs Aging. 2022 Mar;39(3):223–234. Epub 2022 Mar 9. PMID: 35260994; PMCID: PMC8934762. DOI:10.1007/s40266-022-00927-0.
   PubMed Web of Science ®Google Scholar
• Falcone M, Paul M, Tiseo G, et al. ESCMID Study Group for Infections in the Elderly (ESGIE). Considerations for the optimal management of antibiotic therapy in elderly patients. J Glob Antimicrob Resist. 2020 Sep;22:325–333. Epub 2020 Mar 9. PMID: 32165285. DOI:10.1016/j.jgar.2020.02.022
   PubMed Web of Science ®Google Scholar
• Koziatek C, Klein N, Mohan S, et al. Use of a telehealth follow-up system to facilitate treatment and discharge of emergency department patients with severe cellulitis. Am J Emerg Med. 2021;41:184–189.
   PubMed Web of Science ®Google Scholar
• Patel M, Smalley S, Dubrovskaya Y, et al. Dalbavancin use in the emergency department setting. Ann Pharmacother. 2019;53(11):1093–1101. DOI:10.1177/1060028019855159
   PubMed Web of Science ®Google Scholar
• Falcone M, Concia E, Giusti M, et al. Acute bacterial skin and skin structure infections in internal medicine wards: old and new drugs. Intern Emerg Med. 2016 Aug;11(5):637–648. Epub 2016 Apr 15. PMID: 27084183. DOI:10.1007/s11739-016-1450-6.
   PubMed Web of Science ®Google Scholar
• Boucher HW, Wilcox M, Talbot GH, et al. Once- weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169–2179. DOI:10.1056/NEJMoa1310480.
   PubMed Web of Science ®Google Scholar
• Andreoni M, Bassetti M, Corrao S, et al. The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives. Expert Rev Anti Infect Ther. 2021 Sep;19(9):1125–1134. Epub 2021 Mar 16. PMID: 33682593. DOI:10.1080/14787210.2021.1894130.
   PubMed Web of Science ®Google Scholar
• Volpicelli L, Venditti M, Oliva A. Acute bacterial skin and skin structure infections in pediatric patients: potential role of dalbavancin. Expert Rev Anti Infect Ther. 2023 Apr;21(4):329–341. Epub 2023 Feb 27. PMID: 36803139. DOI:10.1080/14787210.2023.2182769.
   PubMed Web of Science ®Google Scholar
• Guidance for industry acute bacterial skin and skin structure infections: developing drugs for treatment [Internet]. U S dep heal hum serv food drug adm cent drug eval res. 2013. Available from: https://www.fda.gov/files/drugs/published/Acute-Bacterial-Skin-and-Skin-Structure-Infections—Developing-Drugs-for-Treatment.pdf
   Google Scholar
• Lee CY, Kunin CM, Chang C, et al. Development of a prediction model for bacteremia in hospitalized adults with cellulitis to aid in the efficient use of blood cultures: a retrospective cohort study. BMC Infect Dis. 2016; Oct 19;16(1):581. DOI: 10.1186/s12879-016-1907-2. PMID: 27756213; PMCID: PMC5070006.
   PubMedGoogle Scholar
• Christensen KLY, Holman RC, Steiner CA, et al. Infectious disease hospitalizations in the United States. Clin Infect Dis. 2009;49(7):1025–1035. DOI:10.1086/605562
   PubMed Web of Science ®Google Scholar
• Goettsch WG, Bouwes Bavinck JN, Herings RM. Burden of illness of bacterial cellulitis and erysipelas of the leg in the Netherlands. J Eur Acad Dermatol Venereol. 2006;20:834–839.
   PubMed Web of Science ®Google Scholar
• Cranendonk DR, Lavrijsen APM, Prins JM, et al. Cellulitis: current insights into pathophysiology and clinical management. Neth J Med. 2017;75(9):366–378.
   PubMed Web of Science ®Google Scholar
• Oliva A, Stefani S, Venditti M, et al. Biofilm-Related Infections in Gram-Positive Bacteria and the Potential Role of the Long-Acting Agent Dalbavancin. Front Microbiol. 2021;12:749685.
   PubMed Web of Science ®Google Scholar
• Sartelli M, Guirao X, Hardcastle TC, et al. WSES/SIS-E consensus conference: recommendations for the management of skin and soft-tissue infections. World J Emerg Surg. [Internet]. 2018;13:p. 58. Available from 2018: https://wjes.biomedcentral.com/articles/10.1186/s13017-018-0219–9
   Google Scholar
• Barbic D, Chenkin J, Cho DD, et al. In patients presenting to the emergency department with skin and soft tissue infections what is the diagnostic accuracy of point-of-care ultrasonography for the diagnosis of abscess compared to the current standard of care? A systematic review and meta-analysis. BMJ Open. 2017 Jan 10;7(1):e013688. Erratum in: BMJ Open. 2017 Sep 14;7(9):e013688corr1. PMID: 28073795; PMCID: PMC5253602. DOI:10.1136/bmjopen-2016-013688
   PubMed Web of Science ®Google Scholar
• Counselman FL, Sanders A, Slovis CM, et al. The status of bedside ultrasonography training in emergency medicine residency programs. Acad Emerg Med. 2003;10(1):37–42. DOI:10.1197/aemj.10.1.37
   PubMed Web of Science ®Google Scholar
• Tayal VS, Hasan N, Norton HJ, et al. The effect of soft-tissue ultrasound on the management of cellulitis in the emergency department. Acad Emerg Med. 2006 Apr;13(4):384–388. Epub 2006 Mar 10. PMID: 16531602. DOI:10.1197/j.aem.2005.11.074.
   PubMed Web of Science ®Google Scholar
• Mower WR, Crisp JG, Krishnadasan A, et al. Effect of initial bedside ultrasonography on emergency department skin and soft tissue infection management. Ann Emerg Med. 2019 Sep;74(3):372–380. Epub 2019 Mar 27. PMID: 30926187. DOI:10.1016/j.annemergmed.2019.02.002.
   PubMed Web of Science ®Google Scholar
• Marin JR, Dean AJ, Bilker WB, et al. Emergency ultrasound assisted examination of skin and soft tissue infections in the pediatric emergency department. Acad Emerg Med. 2013;20(6):545–553. DOI:10.1111/acem.12148
   PubMed Web of Science ®Google Scholar
• Marin JR, Bilker W, Launternbach E, et al. Reliability of clinical examinations for pediatric skin and soft-tissue infections. Pediatrics. 2010;126(5):925–930. DOI:10.1542/peds.2010-1039
   PubMed Web of Science ®Google Scholar
• Rubino CM, Bhavnani SM, Moeck G, et al. Population pharmacokinetic analysis for a single 1200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials. Antimicrob Agents Chemother. 2015;59(6):3365–3372. DOI:10.1128/AAC.00176-15
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Calic D, Schweizer F, et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs. 2010;70(7):859–886. DOI:10.2165/11534440-000000000-00000
   PubMed Web of Science ®Google Scholar
• Smith JR, Roberts KD, Rybak MJ. Dalbavancin: a novel lipoglycopeptide antibiotic with extended activity against Gram-positive infections. Infect Dis Ther. 2015;4(3):245–258.
   PubMed Web of Science ®Google Scholar
• Bailey J, Summers KM. Dalbavancin: a new lipoglycopeptide antibiotic. Am J Health Syst Pharm. 2008;65(7):599–610.
   PubMed Web of Science ®Google Scholar
• Carrothers TJ, Chittenden JT, Critchley I. Dalbavancin population pharmacokinetic modeling and target attainment analysis. Clin Pharmacol Drug Dev. 2020 Jan;9(1):21–31.
   PubMed Web of Science ®Google Scholar
• Marbury T, Dowell JA, Seltzer E, et al. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment. J Clin Pharmacol. 2009;49(4):465–476.
   PubMed Web of Science ®Google Scholar
• Nicolau DP, Sun HK, Seltzer E, et al. Pharmacokinetics of dalbavancin in plasma and skin blister fluid. J Antimicrob Chemother. 2007;60(3):681–684. DOI:10.1093/jac/dkm263.
   PubMed Web of Science ®Google Scholar
• Pea F. Practical concept of pharmacokinetics/pharmacodynamics in the management of skin and soft tissue infections. Curr Opin Infect Dis. 2016;29(2):153–159.
   PubMed Web of Science ®Google Scholar
• Dorr MB, Jabes D, Cavaleri M, et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semisynthetic glycopeptide. J Antimicrob Chemother. 2005;55(Suppl 2):ii25–30. DOI:10.1093/jac/dki008
   PubMedGoogle Scholar
• Roberts KD, Sulaiman RM, Rybak MJ. Dalbavancin and oritavancin: an innovative approach to the treatment of Gram-positive infections. Pharmacotherapy. 2015;35(10):935–948.
   PubMed Web of Science ®Google Scholar
• Riccobono E, Giani T, Baldi G, et al. Update on activity of dalbavancin and comparators against clinical isolates of Gram-positive pathogens from Europe and Russia (2017-2018), and on clonal distribution of MRSA. Int J Antimicrob Agents. 2022 Feb;59(2):106503. DOi:10.1016/j.ijantimicag.2021.106503
   PubMed Web of Science ®Google Scholar
• Sader HS, Mendes RE, Duncan LR, et al. Antimicrobial activity of dalbavancin against Staphylococcus aureus with decreased susceptibility to glycopeptides, daptomycin, and/or linezolid from U.S. Medical Centers. Antimicrob Agents Chemother. 2018;62(3):e02397–17. DOi:10.1128/AAC.02397-17.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Mendes RE, Duncan LR, et al. Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015–16. J Antimicrob Chemother. 2018;73(10):2748–2756. DOI:10.1093/jac/dky235.
   PubMed Web of Science ®Google Scholar
• Jones RN, Flamm RK, Sader HS. Surveillance of dalbavancin potency and spectrum in the United States (2012). Diagn Microbiol Infect Dis. 2013;76(1):122–123.
   PubMed Web of Science ®Google Scholar
• Jones RN, Sader HS, Flamm RK. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY antimicrobial surveillance program (2011). Diagn Microbiol Infect Dis. 2013;75(3):304–307.
   PubMed Web of Science ®Google Scholar
• Goldstein EJ, Citron DM, Merriam CV, et al. In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria. Antimicrob Agents Chemother. 2003 Jun;47(6):1968–1971. doi:10.1128/AAC.47.6.1968-1971.2003.
   PubMed Web of Science ®Google Scholar
• Binyamin D, Nitzan O, Azrad M, et al. In Vitro activity of Tedizolid, Dalbavancin, and Ceftobiprole against clostridium difficile. Front Microbiol. 2018 Jun 11;9:1256. DOI:10.3389/fmicb.2018.01256.
   PubMed Web of Science ®Google Scholar
• Jones RN, Farrell DJ, Flamm RK, et al. Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin. Diagn Microbiol Infect Dis. 2015;82(1):73–77. DOI:10.1016/j.diagmicrobio.2015.01.017
   PubMed Web of Science ®Google Scholar
• Citron DM, Tyrrell KL, Goldstein EJ. Comparative in vitro activities of dalbavancin and seven comparator agents against 41 Staphylococcus species cultured from osteomyelitis infections and 18 VISA and hVISA strains. Diagn Microbiol Infect Dis. 2014;79(4):438–440.
   PubMed Web of Science ®Google Scholar
• Leuthner KD, Buechler KA, Kogan D, et al. Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Ther Clin Risk Manag. 2016;12:931–940.
   PubMed Web of Science ®Google Scholar
• Biedenbach DJ, Ross JE, Fritsche TR, et al. Activity of Dalbavancin Tested against Staphylococcus spp. and β-Hemolytic Streptococcus spp. Isolated from 52 geographically diverse medical centers in the United States. J Clin Microbiol. 2007;45(3):998–1004. DOI:10.1128/JCM.02368-06
   PubMed Web of Science ®Google Scholar
• Lepak A, Marchillo K, VanHecker J, et al. Impact of glycopeptide resistance in Staphylococcus aureus on the dalbavancin in vivo pharmacodynamic target. Antimicrob Agents Chemother. 2015;59(12):7833–7836. DOI:10.1128/AAC.01717-15
   PubMed Web of Science ®Google Scholar
• Simonetti O, Lucarini G, Morroni G, et al. New evidence and insights on dalbavancin and wound healing in a mouse model of skin infection. Antimicrob Agents Chemother. 2020;64(4):e02062–19. DOI:10.1128/AAC.02062-19.
   PubMed Web of Science ®Google Scholar
• Johnson DM, Fritsche TR, Sader HS, et al. Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions. Int J Antimicrob Agents. 2006;27(6):557–560. DOI:10.1016/j.ijantimicag.2005.12.015
   PubMed Web of Science ®Google Scholar
• Xhemali X, Smith JR, Kebriaei R, et al. Evaluation of dalbavancin alone and in combination with beta-lactam antibiotics against resistant phenotypes of Staphylococcus aureus. J Antimicrob Chemother. 2019;74:82–86.
   PubMed Web of Science ®Google Scholar
• Kebriaei R, Rice SA, Stamper KC, et al. Dalbavancin alone and in combination with ceftaroline against four different phenotypes of Staphylococcus aureus in a simulated pharmacodynamic/pharmacokinetic model. Antimicrob Agents Chemother. 2019;63(4):e01743–18. DOI:10.1128/AAC.01743-18.
   PubMed Web of Science ®Google Scholar
• Aktas G, Derbentli S. In vitro activity of daptomycin combined with dalbavancin and linezolid, and dalbavancin with linezolid against MRSA strains. J Antimicrob Chemother. 2017;72(2):441–443.
   PubMed Web of Science ®Google Scholar
• Cacopardo B, Cattaneo D, Cortese F, et al. Role of dalbavancin as combination therapy: evidence from the literature and clinical scenarios. Exp Rev Anti-Infective Ther. 2022;20(7):997–1004. DOI:10.1080/14787210.2022.2060820
   PubMed Web of Science ®Google Scholar
• Sivori F, Cavallo I, Kovacs D, et al. Role of extracellular DNA in dalbavancin activity against methicillin-resistant staphylococcus aureus (MRSA) biofilms in patients with skin and soft tissue infections. Microbiol Spectr. 2022 Apr 27;10(2):e0035122. DOI:10.1128/spectrum.00351-22.
   PubMed Web of Science ®Google Scholar
• Díaz-Navarro M, Hafian R, Manzano I, et al. A dalbavancin lock solution can reduce enterococcal biofilms after freezing. Infect Dis Ther. 2022 Apr;11(2):743–755. DOI:10.1007/s40121-021-00579-4.
   PubMed Web of Science ®Google Scholar
• Dunne MW, Puttagunta S, Giordano P, et al. A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis. 2016; Mar 1;62(5):545–551. Epub 2015 Nov 26. PMID: 26611777; PMCID: PMC4741365. DOI:10.1093/cid/civ982.
   PubMed Web of Science ®Google Scholar
• Rappo U, Gonzalez PL, Puttagunta S, et al. Single-dose dalbavancin and patient satisfaction in an outpatient setting in the treatment of acute bacterial skin and skin structure infections. J Glob Antimicrob Resist. 2019 Jun;17:60–65. Epub 2019 Feb 20. PMID: 30797084. doi:10.1016/j.jgar.2019.02.007.
   PubMed Web of Science ®Google Scholar
• Gonzalez PL, Rappo U, Akinapelli K, et al. Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs. Drugs Context. 2018 Dec 11;7:212559. PMID: 30574170; PMCID: PMC6292452. DOI:10.7573/dic.212559
   PubMedGoogle Scholar
• Nadipelly J, Raghunath P, Kothapalli J. Efficacy of dalbavancin and telavancin in the treatment of acute bacterial skin and skin structure infections. MAEDICA – a J Clinical Med. 2018;13(3):208–212.
   Google Scholar
• Koziatek C, Mohan S, Caspers C, et al. Experience with dalbavancin for cellulitis in the emergency department and emergency observation unit. Am J Emerg Med. 2018 Jul;36(7):1312–1314. Epub 2017 Nov 20. PMID: 29157791. DOI:10.1016/j.ajem.2017.11.037.
   PubMed Web of Science ®Google Scholar
• Wunsch S, Krause R, Valentin T, et al. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections. Int J Infect Dis. 2019 Apr;81:210–214. Epub 2019 Feb 19. PMID: 30794940. DOi:10.1016/j.ijid.2019.02.013.
   PubMed Web of Science ®Google Scholar
• Tobudic S, Forstner C, Burgmann H, et al. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection. Infection. 2019 Dec;47(6):1013–1020. Epub 2019 Sep 13. Erratum in: Infection. 2019 Nov 18;: PMID: 31520397. DOI:10.1007/s15010-019-01354-x.
   PubMed Web of Science ®Google Scholar
• Bartoletti M, Mikus E, Pascale R, et al. Clinical experience with dalbavancin for the treatment of deep sternal wound infection. J Glob Antimicrob Resist. 2019 Sep;18:195–198. Epub 2019 Mar 27. PMID: 30926464. DOI:10.1016/j.jgar.2019.03.015.
   PubMed Web of Science ®Google Scholar
• Dinh A, Duran C, Pavese P, et al. Dalbavancin French Study Group, French national cohort of first use of dalbavancin: a high proportion of off-label use. Int J Antimicrob Agents. 2019 Nov;54(5):668–672. Epub 2019 Aug 7. PMID: 31400471. DOI:10.1016/j.ijantimicag.2019.08.006
   PubMed Web of Science ®Google Scholar
• Arrieta-Loitegui M, Caro-Teller JM, Ortiz-Pérez S, et al. Effectiveness, safety and cost analysis of dalbavancin in clinical practice. Eur J Hosp Pharm. 2022 Jan;29(1):55–58. Epub 2020 Oct 5. PMID: 33020060; PMCID: PMC8717798. DOI:10.1136/ejhpharm-2020-002315.
   PubMedGoogle Scholar
• Dolan A, Kuge E, Bremmer E, et al. Real world utilization of Dalbavancin at a rural community emergency department. Am J Emerg Med. 2022 Apr;54:253–256. Epub 2022 Feb 6. PMID: 35190304. DOI:10.1016/j.ajem.2022.02.006.
   PubMed Web of Science ®Google Scholar
• Simonetti O, Rizzetto G, Molinelli E, et al. Review: a safety profile of dalbavancin for on- and off-label utilization. Ther Clin Risk Manag. 2021 Mar 22;17:223–232. PMID: 33790563; PMCID: PMC7997409. DOI:10.2147/TCRM.S271445
   PubMed Web of Science ®Google Scholar
• Dunne MW, Talbot GH, Boucher HW, et al. Safety of dalbavancin in the treatment of skin and skin structure infections: a pooled analysis of randomized, comparative studies. Drug Saf. 2016 Feb;39(2):147–157. PMID: 26715497; PMCID: PMC4735234. DOI:10.1007/s40264-015-0374-9.
   PubMed Web of Science ®Google Scholar
• Lodise TP, Fan W, Sulham KA. Hospital admission patterns in adult patients with skin and soft tissue infections: identification of potentially avoidable hospital admissions through a retrospective database analysis. Hosp Pract. 1995;2015(43):137–143.
   Google Scholar
• Sabbatini AK, Nallamothu BK, Kocher KE. Reducing variation in hospital admissions from the emergency department for low-mortality conditions may produce savings. Health Aff. 2014;33(9):1655–1663.
   Web of Science ®Google Scholar
• Revankar N, Ward AJ, Pelligra CG, et al. Modeling economic implications of alternative treatment strategies for acute bacterial skin and skin structure infections. J Med Econ. 2014;17(10):730–740. DOI:10.3111/13696998.2014.941065
   PubMedGoogle Scholar
• Caminiti C, Meschi T, Braglia L, et al. Reducing unnecessary hospital days to improve quality of care through physician accountability: a cluster randomised trial. BMC Health Serv Res. 2013 Jan 10;13(1):14. PMID: 23305251; PMCID: PMC3577481. DOI:10.1186/1472-6963-13-14
   PubMedGoogle Scholar
• Shojania KG, Duncan BW, McDonald KM, et al. Safe but sound: patient safety meets evidence-based medicine. JAMA. 2002;288(4):508–513.
   PubMed Web of Science ®Google Scholar
• Moran GJ, Krishnadasan A; EMERGEncy ID Net Study Group, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006 Aug 17;355(7):666–674. PMID: 16914702. DOI:10.1056/NEJMoa055356.
   PubMed Web of Science ®Google Scholar
• Falcone M, Meier JJ, Marini MG, et al. Diabetes and acute bacterial skin and skin structure infections. Diabet Res Clin Pract. 2021 Apr;174:108732. Epub 2021 Mar 5. PMID: 33676996. DOI:10.1016/j.diabres.2021.108732.
   PubMed Web of Science ®Google Scholar
• Lipsky BA, Kollef MH, Miller LG, et al. Predicting bacteremia among patients hospitalized for skin and skin-structure infections: derivation and validation of a risk score. Infect Control Hosp Epidemiol. 2010 Aug;31(8):828–837. PMID: 20586653. DOI:10.1086/654007.
   PubMed Web of Science ®Google Scholar
• Tay EY, Thirumoorthy T, Pang SM, et al. Clinical outcomes of bacteraemia in cellulitis of the leg. Clin Exp Dermatol. 2014 Aug;39(6):683–688. Epub 2014;Jul 1. PMID: 24985315. DOI:10.1111/ced.12366.
   PubMed Web of Science ®Google Scholar
• Falcone M, Serra P, Venditti M. Serious infections due to methicillin-resistant Staphylococcus aureus: an evolving challenge for physicians. Eur J Intern Med. 2009 Jul;20(4):343–347. Epub 2008;Nov 1. PMID: 19524170. DOI:10.1016/j.ejim.2008.08.016.
   PubMed Web of Science ®Google Scholar
• Venditti M, Falcone M, Micozzi A, et al. Staphylococcus aureus bacteremia in patients with hematologic malignancies: a retrospective case-control study. Haematologica. 2003 Aug;88(8):923–930. PMID: 12935981.
   PubMed Web of Science ®Google Scholar
• Perl B, Gottehrer NP, Raveh D, et al. Cost effectiveness of blood cultures for adult patients with cellulitis. Clin Infect Dis. 1999;29(6):1483–1488. DOI:10.1086/313525
   PubMed Web of Science ®Google Scholar
• Paolo WF, Poreda AR, Grant W, et al. Blood culture results do not affect treatment in complicated cellulitis. J Emerg Med. 2013;45(2):163–167. DOI:10.1016/j.jemermed.2013.01.016
   PubMed Web of Science ®Google Scholar
• Sadow KB, Chamberlain JM. Blood cultures in the evaluation of children with cellulitis. Pediatrics. 1998;101(3):e4.
   PubMed Web of Science ®Google Scholar
• Stevenson A, Hider P, Than M. The utility of blood cultures in the management of non-facial cellulitis appears to be low. 100 Years Ago In The NZMJ. 2005;118:1.
   Google Scholar
• Taniguchi T, Tsuha S, Shiiki S, et al. High yield of blood cultures in the etiologic diagnosis of cellulitis, erysipelas, and cutaneous abscess in elderly patients. Open Forum Infect Dis. 2022 Jun 24;9(7):ofac317. PMID: 35899281; PMCID: PMC9310324. DOI:10.1093/ofid/ofac317
   PubMed Web of Science ®Google Scholar
• Gunderson CG, Martinello RA. A systematic review of bacteremias in cellulitis and erysipelas. J Infect. 2012 Feb;64(2):148–155. Epub 2011 Nov 11. PMID: 22101078. DOI:10.1016/j.jinf.2011.11.004.
   PubMed Web of Science ®Google Scholar
• Collazos J, de la Fuente B, de la Fuente J, et al. Factors associated with sepsis development in 606 Spanish adult patients with cellulitis. BMC Infect Dis. 2020 Mar 12;20(1):211. PMID: 32164590; PMCID: PMC7066725. DOI:10.1186/s12879-020-4915-1
   PubMed Web of Science ®Google Scholar
• Micek ST, Hoban AP, Pham V, et al. Bacteremia increases the risk of death among patients with soft-tissue infections. Surg Infect (Larchmt). 2010;11(2):169–176. DOI:10.1089/sur.2009.007
   PubMed Web of Science ®Google Scholar
• Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis. 2014;59(2):e10. DOI:10.1093/cid/ciu296
   PubMed Web of Science ®Google Scholar
• Obaitan I, Dwyer R, Lipworth AD, et al. Failure of antibiotics in cellulitis trials: a systematic review and meta-analysis. Am J Emerg Med. 2016;34(8):1645–1652. DOI:10.1016/j.ajem.2016.05.064
   PubMed Web of Science ®Google Scholar
• Raff AB, Kroshinsky D. Cellulitis: a review. JAMA. 2016;316(3):325–337.
   PubMed Web of Science ®Google Scholar
• Tay EY, Fook-Chong S, Oh CC, et al. Cellulitis recurrence score: a tool for predicting recurrence of lower limb cellulitis. J Am Acad Dermatol. 2015 Jan;72(1):140–145. Epub 2014 Oct 16. PMID: 25443627. DOI:10.1016/j.jaad.2014.08.043.
   PubMed Web of Science ®Google Scholar
• Pizzuti AG, Murray EY, Wagner JL, et al. Financial analysis of dalbavancin for acute bacterial skin and skin structure infections for self-pay patients. Infect Dis Ther. 2020 Dec;9(4):1043–1053. Epub 2020;Oct 21. PMID: 33083894; PMCID: PMC7680485. DOI:10.1007/s40121-020-00347-w.
   PubMed Web of Science ®Google Scholar
• Edelsberg J, Berger A, Weber DJ, et al. Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections. Infect Control Hosp Epidemiol. 2008;29(2):160–169. DOI:10.1086/526444
   PubMed Web of Science ®Google Scholar
• Nathwani D, Dryden M, Garau J. Early clinical assessment of response to treatment of skin and soft-tissue infections: how can it help clinicians? Perspectives from Europe. Int J Antimicrob Agents. 2016 Aug;48(2):127–136. Epub 2016 May 25. PMID: 27283729. DOI:10.1016/j.ijantimicag.2016.04.023.
   PubMed Web of Science ®Google Scholar
• Moran GJ, Fang E, Corey GR, et al. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014;14(8):696–705. DOI:10.1016/S1473-3099(14)70737-6
   PubMed Web of Science ®Google Scholar
• Prokocimer P, De Anda C, Fang E, et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013;309(6):559–569. DOI:10.1001/jama.2013.241
   PubMed Web of Science ®Google Scholar
• Cojutti PG, Merelli M, Bassetti M, et al. Proactive therapeutic drug monitoring (TDM) may be helpful in managing long-term treatment with linezolid safely: findings from a monocentric, prospective, open-label, interventional study. J Antimicrob Chemother. 2019 Dec 1;74(12):3588–3595. PMID: 31504570. DOI:10.1093/jac/dkz374
   PubMed Web of Science ®Google Scholar
• Pea F, Furlanut M, Cojutti P, et al. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother. 2010 Nov;54(11):4605–4610. Epub 2010 Aug 23. PMID: 20733043; PMCID: PMC2976143. DOI:10.1128/AAC.00177-10.
   PubMed Web of Science ®Google Scholar
• Taylor K, Williamson J, Luther V, et al. Evaluating the use of dalbavancin for off-label indications. Infect Dis Rep. 2022 Apr 11;14(2):266–272. PMID: 35447884; PMCID: PMC9026399. DOI:10.3390/idr14020032
   PubMed Web of Science ®Google Scholar
• Falcone M, Russo A, Pompeo ME, et al. Retrospective case-control analysis of patients with staphylococcal infections receiving daptomycin or glycopeptide therapy. Int J Antimicrob Agents. 2012 Jan;39(1):64–68. Epub 2011 Nov 1. PMID: 22047703. DOI:10.1016/j.ijantimicag.2011.09.011.
   PubMed Web of Science ®Google Scholar
• Falcone M, Russo A, Venditti M, et al. Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2013 Dec;57(11):1568–1576. Epub 2013 Sep 17. PMID: 24046298. DOI:10.1093/cid/cit582.
   PubMed Web of Science ®Google Scholar
• Dryden M, Saeed K, Townsend R, et al. Antibiotic stewardship and early discharge from hospital: impact of a structured approach to antimicrobial management. J Antimicrob Chemother. 2012;67(9):2289–2296. DOI:10.1093/jac/dks193
   PubMed Web of Science ®Google Scholar
• Gray A, Dryden M, Charos A. Antibiotic management and early discharge from hospital: an economic analysis. J Antimicrob Chemother. 2012;67(9):2297–2302.
   PubMed Web of Science ®Google Scholar
• Talan DA, Mower WR, Lovecchio FA, et al. Pathway with single-dose long-acting intravenous antibiotic reduces emergency department hospitalizations of patients with skin infections. Acad Emerg Med. 2021 Oct;28(10):1108–1117. Epub 2021 May 5. PMID: 33780567; PMCID: PMC8597095. DOI:10.1111/acem.14258.
   PubMed Web of Science ®Google Scholar
• Krsak M, Morrisette T, Miller M, et al. Advantages of outpatient treatment with long-acting lipoglycopeptides for serious gram-positive infections: a review. Pharmacotherapy. 2020 May;40(5):469–478. Epub 2020 Apr 23. PMID: 32239771. DOI:10.1002/phar.2389.
   PubMed Web of Science ®Google Scholar
• Bork JT, Heil EL, Berry S, et al. Dalbavancin use in vulnerable patients receiving outpatient parenteral antibiotic therapy for invasive Gram-positive infections. Infect Dis Ther. 2019;8(2):171–184. Available from: http://link.springer.com/10.1007/s40121-019-0247–0
   PubMed Web of Science ®Google Scholar
• Attwood LO, McKechnie M, Vujovic O, et al. Review of management priorities for invasive infections in people who inject drugs: highlighting the need for patient-centred multidisciplinary care. Med J Aust. 2022 Jul 18;217(2):102–109. Epub 2022 Jun 26. PMID: 35754144; PMCID: PMC9539935. DOI:10.5694/mja2.51623
   PubMed Web of Science ®Google Scholar
• Hemmige V, McNulty M, Silverman E, et al. Recurrent skin and soft tissue infections in HIV-infected patients during a 5-year period: incidence and risk factors in a retrospective cohort study. BMC Infect Dis. 2015;15(1):455.
   PubMedGoogle Scholar
• Waldron C, Solon JG, O’Gorman J, et al. Necrotizing fasciitis: the need for urgent surgical intervention and the impact of intravenous drug use. Surgeon. 2015;13(4):194–199. DOI:10.1016/j.surge.2014.01.005
   PubMed Web of Science ®Google Scholar
• Grau D, Clarivet B, Lotthé A, et al. Complications with peripherally inserted central catheters (PICCs) used in hospitalized patients and outpatients: a prospective cohort study. Antimicrob Resist Infect Control. 2017;6(1):18. DOI:10.1186/s13756-016-0161-0
   PubMed Web of Science ®Google Scholar
• Antosz K, Al-Hasan MN, Lu ZK, et al. Clinical utility and cost effectiveness of long-acting lipoglycopeptides used in deep-seated infections among patients with social and economic barriers to care. Pharmacy. 2022;10(1):1. DOI:10.3390/pharmacy10010001
   Web of Science ®Google Scholar
• Agarwal R, Bartsch SM, Kelly BJ, et al. Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis. Clin Microbiol Infect. 2018 Apr;24(4):361–368. Epub 2017 Sep 4. PMID: 28882727; PMCID: PMC5925741. DOI:10.1016/j.cmi.2017.08.028.
   PubMed Web of Science ®Google Scholar
• Marcellusi A, Viti R, Sciattella P, et al. Economic evaluation of the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) from the national payer perspective: introduction of a new treatment to the patient journey. A simulation of three European countries. Expert Rev Pharmacoecon Outcomes Res. 2019 Oct;19(5):581–599. Epub 2019 Feb 4. PMID: 30714834.127. DOI:10.1080/14737167.2019.1569516.
   PubMed Web of Science ®Google Scholar
• Marcellusi A, Bini C, Andreoni M, et al. Budget impact analysis of dalbavancin in the treatment of acute bacterial skin and skin structure infections in three European countries. Clin Drug Investig. 2020 Apr;40(4):305–318. PMID: 32034687. DOI:10.1007/s40261-020-00891-w.
   PubMed Web of Science ®Google Scholar
• Streifel AC, Sikka MK, Bowen CD, et al. Dalbavancin use in an academic medical centre and associated cost savings. Int J Antimicrob Agents. 2019 2nd;54(5):652–654. DOI:10.1016/j.ijantimicag.2019.08.007.
   PubMed Web of Science ®Google Scholar
• Kaiser Family Foundation. Hospital adjusted expenses per inpatient day by ownership. Accessed 2022 Dec 4 https://www.kff.org/health-costs/state-indicator/expenses-per-inpatient-day-by-ownership/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D.
   Google Scholar
• Ektare V, Khachatryan A, Xue M, et al. Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care setting. J Med Econ. 2015;18(12):1092–1101. DOI:10.3111/13696998.2015.1078339
   PubMed Web of Science ®Google Scholar
• McCarthy MW, Keyloun KR, Gillard P, et al. Dalbavancin reduces hospital stay and improves productivity for patients with acute bacterial skin and skin structure infections: the ENHANCE trial. Infect Dis Ther. 2020 Mar; 9(1):53–67. DOI:10.1007/s40121-019-00275-4.
   PubMed Web of Science ®Google Scholar
• Wong CH, Khin LW, Heng KS, et al. The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med. 2004 Jul;32(7):1535–1541. PMID: 15241098. DOI:10.1097/01.ccm.0000129486.35458.7d.
   PubMed Web of Science ®Google Scholar
• Lagi F, Ottino L, Mantengoli E, et al. Early discharge criteria in patients with acute bacterial skin and skin structure infections in a large tertiary-care teaching hospital in Florence, Italy. Eur J Clin Microbiol Infect Dis. 2019 Sep;38(9):1781–1785. Epub 2019 Jun 20. PMID: 31222396; PMCID: PMC6695376. DOI:10.1007/s10096-019-03609-9.
   PubMed Web of Science ®Google Scholar
• Viallon A, Marjollet O, Berthelot P, et al. Risk factors associated with methicillin-resistant Staphylococcus aureus infection in patients admitted to the ED. Am J Emerg Med. 2007 Oct;25(8):880–886. PMID: 17920971. DOI:10.1016/j.ajem.2007.01.013.
   PubMed Web of Science ®Google Scholar
• Karanika S, Zervou FN, Zacharioudakis IM, et al. Risk factors for meticillin-resistant Staphylococcus aureus colonization in dialysis patients: a meta-analysis. J Hosp Infect. 2015 Nov;91(3):257–263. Epub 2015 Aug 28. PMID: 26428959. DOI:10.1016/j.jhin.2015.07.014.
   PubMed Web of Science ®Google Scholar
• Lee AS, de Lencastre H, Garau J, et al. Methicillin-resistant Staphylococcus aureus. Nat Rev Dis Primers. 2018; May 31;4(1). PMID: 29849094. 18033. DOI:10.1038/nrdp.2018.33.
   PubMed Web of Science ®Google Scholar